[1]
|
Xu, J., Murphy, S.L., Kochanek, K.D., et al. (2016) Deaths: Final Data for 2013. National Vital Statistics Reports, 64, 1-119.
|
[2]
|
Malyszko, J., Kozlowski, L., Kozlowska, K., et al. (2017) Cancer and the Kidney: Dangereoux Liasons or Price Paid for the Progress in Medicine? Oncotarget, 8, 66601-66619. https://doi.org/10.18632/oncotarget.18094
|
[3]
|
Salahudeen, A.K. and Bonventre, J.V. (2013) Onconephrology: The Latest Frontier in the War against Kidney Disease. Journal of the American Society of Nephrology, 24, 26-30. https://doi.org/10.1681/ASN.2012070690
|
[4]
|
Stewart, A.F. (2005) Clinical Practice. Hypercalcemia Associated with Cancer. The New England Journal of Medicine, 352, 373-379. https://doi.org/10.1056/NEJMcp042806
|
[5]
|
Rosner, M.H. and Dalkin, A.C. (2014) Electrolyte Disorders Associ-ated with Cancer. Advances in Chronic Kidney Disease, 21, 7-17. https://doi.org/10.1053/j.ackd.2013.05.005
|
[6]
|
Chen, Y.-C., Sosnoski, D.M. and Mastro, A.M. (2010) Breast Cancer Metastasis to the Bone: Mechanisms of Bone Loss. Breast Cancer Research, 12, 215.
|
[7]
|
Patel, A.M. and Goldfarb, S. (2010) Got Calcium? Welcome to the Calcium-Alkali Syndrome. Journal of the American Society of Neph-rology, 21, 1440-1443. https://doi.org/10.1681/ASN.2010030255
|
[8]
|
Karras, A., De Montpreville, V., Fakhouri, F., et al. (2005) Renal and Thymic Pathology in Thymoma-Associated Nephropathy: Report of 21 Cases and Review of the Literature. Nephrology, Dialysis, Transplantation, 20, 1075-1082.
|
[9]
|
Jhaveri, K.D., Shah, H.H., Patel, C., et al. (2014) Glomerular Diseases Associated with Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Ad-vances in Chronic Kidney Disease, 21, 48-55.
https://doi.org/10.1053/j.ackd.2013.08.003
|
[10]
|
Mallouk, A., Pham, P.-T.T. and Pham, P.-C.T. (2006) Concurrent FSGS and Hodgkin’s Lymphoma: Case Report and Literature Review on the Link between Nephrotic Glomerulopathies and Hematological Malignancies. Clinical and Experimental Nephrology, 10, 284-289. https://doi.org/10.1007/s10157-006-0437-4
|
[11]
|
Da’As, N., Polliack, A., Cohen, Y., et al. (2001) Kidney In-volvement and Renal Manifestations in Non-Hodgkin’s Lymphoma and Lymphocytic Leukemia: A Retrospective Study in 700 Patients. European Journal of Haematology, 67, 158-164. https://doi.org/10.1034/j.1600-0609.2001.5790493.x
|
[12]
|
Cairo, M.S. and Bishop, M. (2004) Tumour Lysis Syn-drome: New Therapeutic Strategies and Classification. British Journal of Haematology, 127, 3-11. https://doi.org/10.1111/j.1365-2141.2004.05094.x
|
[13]
|
Howard, S.C., Jones, D.P. and Pui, C.-H. (2011) The Tu-mor Lysis Syndrome. New England Journal of Medicine, 364, 1844-1854. https://doi.org/10.1056/NEJMra0904569
|
[14]
|
Shimada, M., Johnson, R.J., May, W.S., et al. (2009) A Novel Role for Uric Acid in Acute Kidney Injury Associated with Tumour Lysis Syndrome. Nephrology Dialysis Transplantation, 24, 2960-2964.
https://doi.org/10.1093/ndt/gfp330
|
[15]
|
Laskin, B.L., Goebel, J., Davies, S.M., et al. (2011) Small Vessels, Big Trouble in the Kidneys and Beyond: Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Blood, 118, 1452-1462.
https://doi.org/10.1182/blood-2011-02-321315
|
[16]
|
Besbas, N., Karpman, D., Landau, D., et al. (2006) A Classi-fication of Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Related Disorders. Kidney In-ternational, 70, 423-431.
https://doi.org/10.1038/sj.ki.5001581
|
[17]
|
Copelovitch, L. and Kaplan, B.S. (2008) The Thrombotic Microangiop-athies. Pediatric Nephrology, 23, 1761-1767.
https://doi.org/10.1007/s00467-007-0616-x
|
[18]
|
Pankhurst, T., Savage, C.O.S., Gordon, C., et al. (2004) Malig-nancy Is Increased in ANCA-Associated Vasculitis. Rheumatology (Oxford, England), 43, 1532-1535. https://doi.org/10.1093/rheumatology/keh374
|
[19]
|
Francis, K.K., Kalyanam, N., Terrell, D.R., et al. (2007) Dis-seminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a System-atic Review of Published Cases. The Oncologist, 12, 11-19. https://doi.org/10.1634/theoncologist.12-1-11
|
[20]
|
Lam, A.Q. and Humphreys, B.D. (2012) Onco-Nephrology: AKI in the Cancer Patient. Clinical Journal of the American Society of Nephrology, 7, 1692-1700. https://doi.org/10.2215/CJN.03140312
|
[21]
|
Campbell, G.A., Hu, D. and Okusa, M.D. (2014) Acute Kidney Injury in the Cancer Patient. Advances in Chronic Kidney Disease, 21, 64-71. https://doi.org/10.1053/j.ackd.2013.08.002
|
[22]
|
Humphreys, B.D., Soiffer, R.J. and Magee, C.C. (2005) Renal Failure Associated with Cancer and Its Treatment: An Update. Journal of the American Society of Nephrology: JASN, 16, 151-161.
|
[23]
|
Perazella, M.A. (2012) Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents. Clinical Journal of the American Society of Nephrology, 7, 1713-1721. https://doi.org/10.2215/CJN.02780312
|
[24]
|
Izzedine, H. and Perazella, M.A. (2017) Adverse Kidney Effects of Epidermal Growth Factor Receptor Inhibitors. Nephrology Dialysis Transplantation, 32, 1089-1097. https://doi.org/10.1093/ndt/gfw467
|
[25]
|
Izzedine, H., Mateus, C., Boutros, C., et al. (2017) Renal Effects of Immune Checkpoint Inhibitors. Nephrology Dialysis Transplantation, 32, 936-942.
|
[26]
|
Launay-Vacher, V., Aapro, M., de Castro, G., et al. (2015) Renal Effects of Molecular Targeted Thera-pies in Oncology: A Review by the Cancer and the Kidney International Network (C-KIN). Annals of Oncology, 26, 1677-1684.
https://doi.org/10.1093/annonc/mdv136
|
[27]
|
Launay-Vacher, V. and Deray, G. (2009) Hypertension and Pro-teinuria: A Class-Effect of Antiangiogenic Therapies. Anti-Cancer Drugs, 20, 81-82. https://doi.org/10.1097/CAD.0b013e3283161012
|
[28]
|
van Cutsem, E., Tabernero, J., Lakomy, R., et al. (2012) Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen. Journal of Clinical Oncology, 30, 3499-3506.
https://doi.org/10.1200/JCO.2012.42.8201
|
[29]
|
Kelly, R.J., Billemont, B. and Rixe, O. (2009) Renal Toxicity of Targeted Therapies. Targeted Oncology, 4, 121-133.
https://doi.org/10.1007/s11523-009-0109-x
|
[30]
|
Hamid, O., Robert, C., Daud, A., et al. (2013) Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. New England Journal of Medicine, 369, 134-144. https://doi.org/10.1056/NEJMoa1305133
|
[31]
|
Hofmann, L., Forschner, A., Loquai, C., et al. (2016) Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 190-209.
|
[32]
|
Shirali, A.C., Perazella, M.A. and Gettinger, S. (2016) Association of Acute Interstitial Nephritis with Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal of Kidney Diseases, 68, 287-291.
https://doi.org/10.1053/j.ajkd.2016.02.057
|
[33]
|
Cortazar, F.B., Marrone, K.A., Troxell, M.L., et al. (2016) Clini-copathological Features of Acute Kidney Injury Associated with Immune Checkpoint Inhibitors. Kidney International, 90, 638-647.
https://doi.org/10.1016/j.kint.2016.04.008
|
[34]
|
Levey, A.S., De Jong, P.E., Coresh, J., et al. (2011) The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference Report. Kidney Interna-tional, 80, 17-28.
https://doi.org/10.1038/ki.2010.483
|
[35]
|
Coresh, J., Astor, B.C., Greene, T., et al. (2003) Prevalence of Chronic Kidney Disease and Decreased Kidney Function in the Adult US Population: Third National Health and Nutrition Exam-ination Survey. American Journal of Kidney Diseases, 41, 1-12.
|
[36]
|
Levey, A.S., Stevens, L.A., Schmid, C.H., et al. (2009) A New Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 150, 604-612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
|
[37]
|
Collins, A.J., Li, S., Gilbertson, D.T., et al. (2003) Chronic Kidney Disease and Cardiovascular Disease in the Medicare Population. Kidney International Supple-ment, 87, S24-531.
|
[38]
|
Funakoshi, Y., Fujiwara, Y., Kiyota, N., et al. (2016) Validity of New Methods to Evaluate Renal Function in Cancer Patients Treated with Cisplatin. Cancer Chemotherapy and Pharmacology, 77, 281-288.
https://doi.org/10.1007/s00280-016-2966-1
|
[39]
|
Janowitz, T., Williams, E.H., Marshall, A., et al. (2017) New Model for Estimating Glomerular Filtration Rate in Patients with Cancer. Journal of Clinical Oncology, 35, 2798-2805.
|